The purpose of this study is to determine whether sildenafil improves parameters of vascular
function and blood markers involved in development of heart disease in patients with
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT02908490
Ages eligible for Study
18 Years and older
Genders eligible for Study
Accepts Healthy Volunteers
At least one traditional CV risk factor (i.e., older age [men ≥45 years, women ≥55
years], obesity [defined as body mass index (BMI) >30 kg/m2], smoking, hypertension,
hyperlipidemia, diabetes mellitus, family history of premature [defined as diagnosed
at <65 years old] CVD in first-degree relative)
On stable baseline doses of RA medications, defined as no change in dose within past 4
weeks and no anticipated changes over the next 6 months
On no higher than 10 mg per day of prednisone or prednisone-equivalent within past 4
RA disease duration (from symptom onset) of more than 6 months
Having clinical disease activity index (CDAI) of >2.8 but ≤22 (i.e., either low or
moderate disease activity), within 30 days of study enrollment
Aged <18 years
Known personal history of CVD (clinical diagnoses of stroke, transient ischemic
attack, myocardial infarction, acute coronary syndrome, peripheral arterial disease,
percutaneous coronary intervention or coronary bypass graft surgery)
Use of high-dose statins (e.g., atorvastatin 40-80 mg/day or rosuvastatin 20-40
mg/day) currently or within past 3 months, or any dose changes of statins or of blood
pressure medications that may affect endothelial function (i.e.,
angiotensin-converting-enzyme [ACE] inhibitors or angiotensin receptor blockers
[ARBs]) within past 3 months. If on statin or an ACE-I or ARB, there should be no
anticipated dose changes over the next 6 months.
Persons with intra-cardiac and intra-pulmonary shunts, unstable cardiopulmonary
conditions, or anyone on chronic oxygen therapy
Persons taking nitric oxide donors, organic nitrites and nitrates, such as glyceryl
trinitrate (nitroglycerin), sodium nitroprusside, amyl nitrite ("poppers")
Severe hepatic impairment (liver function tests >1.5 times upper limit of normal)
within past 4 weeks
Severe impairment in renal function (serum creatinine ≥1.5 mg/dL) within past 4 weeks
Hypotension (defined as blood pressure [BP] <90/60)
Hereditary degenerative retinal disorders (including genetic disorders of retinal
Persons already taking (or taken within 3 months) sildenafil or other PDE inhibitors
(i.e., tadalafil, vardenafil)
Persons unable to provide voluntary written informed consent
Severe hypertension (BP >170/110)
Persons with HIV/AIDS
All locations for NCT02908490
United States (1)
University of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15213
View full eligibility
Tris trial is registered with FDA with number: NCT02908490. The sponsor of the trial is Kimberly Liang and it is looking for 26 volunteers for the current phase.
Official trial title: Does Sildenafil Improve Endothelial Dysfunction in Rheumatoid Arthritis?
1What's a trial
4Get in touch
What's a trial
Not sure you're well informed about clinical trials? Learn more about their benefits, risks and other important details.
Enter your details like condition, age, gender and other preferences and we will show you a list of all relevant clinical trials.
Review the summary of the selected clinical trial and all the locations near you in order to see if it's of interest to you.
Get in touch
You've found an interesting trial? We'll need a bit more information about you so we can connect you to the doctor in charge.
Some people want to consult their doctor before considering participation in a clinical trial. This is absolutely normal as your doctor should know your medical history and should be able to advise you. If you want you can easily share the information for this trial with your doctor by clicking on the button below.